143 related articles for article (PubMed ID: 23471121)
1. Neurotrophin 3 genotype and emotional adverse effects of osmotic-release oral system methylphenidate (OROS-MPH) in children with attention-deficit/hyperactivity disorder.
Park S; Kim BN; Kim JW; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
J Psychopharmacol; 2014 Mar; 28(3):220-6. PubMed ID: 23471121
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
3. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
[TBL] [Abstract][Full Text] [Related]
4. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
[TBL] [Abstract][Full Text] [Related]
5. Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder.
Song J; Kim SW; Hong HJ; Lee MG; Lee BW; Choi TK; Lee SH; Yook KH
Clin Neuropharmacol; 2014; 37(5):136-41. PubMed ID: 25229170
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of osmotic-release methylphenidate with cognitive-behavioral therapy in adolescents with attention-deficit/hyperactivity disorder and substance use disorders.
Riggs PD; Winhusen T; Davies RD; Leimberger JD; Mikulich-Gilbertson S; Klein C; Macdonald M; Lohman M; Bailey GL; Haynes L; Jaffee WB; Haminton N; Hodgkins C; Whitmore E; Trello-Rishel K; Tamm L; Acosta MC; Royer-Malvestuto C; Subramaniam G; Fishman M; Holmes BW; Kaye ME; Vargo MA; Woody GE; Nunes EV; Liu D
J Am Acad Child Adolesc Psychiatry; 2011 Sep; 50(9):903-14. PubMed ID: 21871372
[TBL] [Abstract][Full Text] [Related]
7. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
[TBL] [Abstract][Full Text] [Related]
8. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
9. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
[TBL] [Abstract][Full Text] [Related]
10. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
[TBL] [Abstract][Full Text] [Related]
11. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
[TBL] [Abstract][Full Text] [Related]
12. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
Golubchik P; Kodesh A; Weizman A
Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
[TBL] [Abstract][Full Text] [Related]
13. Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.
Kim BN; Cummins TD; Kim JW; Bellgrove MA; Hong SB; Song SH; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
Int J Neuropsychopharmacol; 2011 Nov; 14(10):1399-410. PubMed ID: 21733227
[TBL] [Abstract][Full Text] [Related]
14. Norepinephrine transporter gene (SLC6A2) is involved with methylphenidate response in Korean children with attention deficit hyperactivity disorder.
Song J; Song DH; Jhung K; Cheon KA
Int Clin Psychopharmacol; 2011 Mar; 26(2):107-13. PubMed ID: 21127421
[TBL] [Abstract][Full Text] [Related]
15. Parental perceived benefits of OROS-methylphenidate treatment for the child with attention-deficit/hyperactivity disorder and for parents themselves.
Kim JW; Park S; Kim BN; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
Pharmacopsychiatry; 2013 Jun; 46(4):137-46. PubMed ID: 23364873
[TBL] [Abstract][Full Text] [Related]
16. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
[TBL] [Abstract][Full Text] [Related]
17. Examining the heterogeneity of treatment patterns in attention deficit hyperactivity disorder among children and adolescents in the Texas Medicaid population: modeling suboptimal treatment response.
Grebla R; Setyawan J; Park C; Richards KM; Nwokeji ED; Pawaskar M; Haim Erder M; Lawson KA
J Med Econ; 2019 Aug; 22(8):788-797. PubMed ID: 30983465
[No Abstract] [Full Text] [Related]
18. Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder.
Park SY; Kim EJ; Cheon KA
J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):633-40. PubMed ID: 26402385
[TBL] [Abstract][Full Text] [Related]
19. Neurotrophin-3 gene, intelligence, and selective attention deficit in a Korean sample with attention-deficit/hyperactivity disorder.
Cho SC; Kim HW; Kim BN; Kim JW; Shin MS; Cho DY; Chung S; Jung SW; Yoo HJ; Chung IW; Chung US; Son JW
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1065-9. PubMed ID: 20576502
[TBL] [Abstract][Full Text] [Related]
20. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
